Health behavior outcomes in stroke survivors prescribed wearables for atrial fibrillation detection stratified by age.

BACKGROUND

Smartwatches have become readily accessible tools for detecting atrial fibrillation (AF). There remains limited data on how they affect psychosocial outcomes and engagement in older adults. We examine the health behavior outcomes of stroke survivors prescribed smartwatches for AF detection stratified by age.

METHODS

We analyzed data from the Pulsewatch study, a randomized controlled trial that enrolled patients (≥ 50 years) with a history of stroke or transient ischemic attack and CHA2DS2-VASc ≥ 2. Intervention participants were equipped with a cardiac patch monitor and a smartwatch-app dyad, while control participants wore the cardiac patch monitor for up to 44 days. We evaluated health behavior parameters using standardized tools, including the Consumer Health Activation Index, the Generalized Anxiety Disorder questionnaire, the 12-Item Short Form Health Survey, and wear time of participants categorized into three age groups: Group 1 (ages 50-60), Group 2 (ages 61-69), and Group 3 (ages 70-87). We performed statistical analysis using a mixed-effects repeated measures linear regression model to examine differences amongst age groups.

RESULTS

Comparative analysis between Groups 1, 2 and 3 revealed no significant differences in anxiety, patient activation, perception of physical health and wear time. The use of smartwatch technology was associated with a decrease in perception of mental health for Group 2 compared to Group 1 (β = -3.29,

CONCLUSION

Stroke survivors demonstrated a willingness to use smartwatches for AF monitoring. Importantly, among these study participants, the majority did not experience negative health behavior outcomes or decreased engagement as age increased.

Informations de copyright

© 2024 JGC All rights reserved; www.jgc301.com.

Déclaration de conflit d'intérêts

Dr. McManus reports receiving research support from Apple Computer, Bristol-Myers Squibb, Boehringer-Ingelheim, Fitbit, Pfizer, Samsung, Flexcon, Philips Healthcare, and Biotronik; consultancy fees from Bristol-Myers Squibb, Pfizer, Flexcon, Boston Biomedical Associates/Avania, Fitbit, and Heart Rhythm Society. Dr. Tran reports receiving research grants from Novartis.